Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06067841 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
140
Enrollment target
8
Study locations

NCT06067841 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 140 participants, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (29% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06067841, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
140 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

  • DRUG BMS-986460

Study Locations (8)

Texas

  • Local Institution - 0006 - San Antonio
  • NEXT Oncology - San Antonio

California

  • Stanford Cancer Center - Palo Alto

Florida

  • Florida Cancer Specialists Sarasota Drug Development Unit - Sarasota

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Duke Cancer Institute - Durham

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2023-10-18
Est. Completion 2031-07-27
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06067841

The ClinicalTrials.gov registry entry for NCT06067841 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (29% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which BMS-986460 is the first listed.

NCT06067841 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06067841 about?

NCT06067841 is a clinical study titled "A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

What is the current status of trial NCT06067841?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-10-18. Estimated completion is 2031-07-27.

What conditions does trial NCT06067841 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06067841?

The interventions under investigation include: BMS-986460 (DRUG).

Who is sponsoring clinical trial NCT06067841?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06067841 being conducted?

This trial has 8 study locations across California, Florida, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.